ASH 2020 | CLL14: Venetoclax plus obinutuzumab for CLL
Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, gives an update on the CLL14 trial (NCT02242942), a Phase III randomized trial comparing venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in patients with chronic lymphocytic leukemia (CLL). Additionally, he outlines how analysis of clonal growth patterns can be used to predict the risk of relapse. Finally, Dr Al-Sawaf discusses the characteristics and outcomes of patients with CLL who have a partial response (PR) to venetoclax combined with obinutuzumab. This analysis found that the most frequent causes of PR after venetoclax plus obinutuzumab were mild residual lymphadenopathy and missing bone marrow samples. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Othman Al-Sawaf, MD, has received research grants from Abbvie, Roche, Janssen, Beigene; and has received honoraria or personal fees from AbbVie, Roche, Janssen, Gilead and AstraZeneca.
